Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 5/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24838705 | 0.97 | UCHL1 (0.44) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL18815574 | 0.88 | ALDH1A1 (0.52) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL18815575 | 0.88 | ALDH1A1 (0.52) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL7605071 | 0.88 | USP30 (0.52) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL15854366 | 0.88 | NPC1 (0.51) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL17396032 | 0.88 | NPC1 (0.51) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL15848455 | 0.87 | KLK7 (0.53) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL4955279 | 0.87 | KLK7 (0.53) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL15848456 | 0.87 | KLK7 (0.53) | UCHL1EPHX2NPC1MEN1KMT2A | |
| SCHEMBL564404 | 0.85 | NPC1 (0.46) | UCHL1EPHX2NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PREP | UCHL1 3021/4885EPHX2 3717/4885NPC1 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.